Haleon PLC Sponsored ADR ( (HLN) ) just unveiled an announcement.
Haleon PLC announced its preliminary full-year results for 2024, highlighting strong financial performance and strategic progress. The company achieved a 5.0% organic revenue growth with a notable 9.8% increase in organic operating profit, driven by gross margin expansion and productivity savings. Haleon proposed a 10% increase in the total dividend payout, reflecting robust free cash flow and reduced leverage, with net debt standing at £7,907m. The company also announced a £500m share buyback program for 2025, signaling confidence in its growth outlook. Haleon’s strategic investments, including an increased stake in its China Joint Venture, position it well for continued growth in 2025 and beyond.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse product portfolio across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). Haleon is known for its trusted brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, which are built on a foundation of scientific innovation and deep human understanding.
YTD Price Performance: 8.05%
Average Trading Volume: 8,940,503
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $45.35B
For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com